ID   SKBR3-LR
AC   CVCL_LG17
DR   cancercelllines; CVCL_LG17
DR   Wikidata; Q54954672
RX   PubMed=24876102;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:49603; Lapatinib (Tykerb; Tyverb).
CC   Sequence variation: Gene deletion; HGNC; 1748; CDH1; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C5214; Breast adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0033 ! SK-BR-3
SX   Female
AG   43Y
CA   Cancer cell line
DT   Created: 15-11-17; Last updated: 05-10-23; Version: 10
//
RX   PubMed=24876102; DOI=10.1158/0008-5472.CAN-13-2053;
RA   Rani S., Corcoran C., Shiels L., Germano S., Breslin S., Madden S.F.,
RA   McDermott M.S., Browne B.C., O'Donovan N., Crown J., Gogarty M.,
RA   Byrne A.T., O'Driscoll L.;
RT   "Neuromedin U: a candidate biomarker and therapeutic target to predict
RT   and overcome resistance to HER-tyrosine kinase inhibitors.";
RL   Cancer Res. 74:3821-3833(2014).
//